Editorial: Targeting Metabolism in Cancer Immunotherapy.
作者信息
Roszik Jason, Tanese Keiji, Ekmekcioglu Suhendan
机构信息
Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
出版信息
Front Immunol. 2018 Sep 11;9:2029. doi: 10.3389/fimmu.2018.02029. eCollection 2018.
Abstract
摘要
相似文献
1
Editorial: Targeting Metabolism in Cancer Immunotherapy.社论：癌症免疫疗法中的代谢靶向
Front Immunol. 2018 Sep 11;9:2029. doi: 10.3389/fimmu.2018.02029. eCollection 2018.
2
Immunosuppression in the tumor microenvironment: where are we standing?肿瘤微环境中的免疫抑制：我们目前的进展如何？
Semin Cancer Biol. 2012 Aug;22(4):273-4. doi: 10.1016/j.semcancer.2012.05.001. Epub 2012 May 15.
3
Editorial: Novel Strategies for Cancer Immunotherapy: Targeting Immune-Mediated Suppressive Mechanisms.社论：癌症免疫疗法的新策略：靶向免疫介导的抑制机制
Front Immunol. 2021 May 3;12:691899. doi: 10.3389/fimmu.2021.691899. eCollection 2021.
4
Targeting Tertiary Lymphoid Structures for Tumor Immunotherapy.靶向三级淋巴结构进行肿瘤免疫治疗。
Methods Mol Biol. 2018;1845:275-286. doi: 10.1007/978-1-4939-8709-2_16.
5
Cancer, obesity and immunometabolism - Connecting the dots.癌症、肥胖与免疫代谢——理清其中的关联。
Cancer Lett. 2018 Mar 28;417:11-20. doi: 10.1016/j.canlet.2017.12.019. Epub 2017 Dec 16.
6
Nanoparticle-Based Phototriggered Cancer Immunotherapy and Its Domino Effect in the Tumor Microenvironment.基于纳米颗粒的光触发癌症免疫治疗及其在肿瘤微环境中的级联效应。
Biomacromolecules. 2018 Jun 11;19(6):1869-1887. doi: 10.1021/acs.biomac.8b00460. Epub 2018 Apr 27.
7
Introduction to the special issue-Barriers and opportunities to cancer immunotherapy in the tumor immune microenvironment.特刊介绍——肿瘤免疫微环境中癌症免疫治疗的障碍与机遇
Semin Immunol. 2020 Jun;49:101421. doi: 10.1016/j.smim.2020.101421. Epub 2020 Dec 9.
8
PTEN Function at the Interface between Cancer and Tumor Microenvironment: Implications for Response to Immunotherapy.PTEN 功能位于癌症与肿瘤微环境的交界处：对免疫治疗反应的影响。
Int J Mol Sci. 2020 Jul 27;21(15):5337. doi: 10.3390/ijms21155337.
9
Tumor Microenvironment, Metabolism, and Immunotherapy.肿瘤微环境、代谢与免疫疗法。
N Engl J Med. 2020 Feb 27;382(9):869-871. doi: 10.1056/NEJMcibr1914890.
10
Targeting the tumor microenvironment by immunotherapy: part 2.免疫疗法靶向肿瘤微环境：第 2 部分。
Immunotherapy. 2011 Nov;3(11):1385-408. doi: 10.2217/imt.11.112.
引用本文的文献
1
Utilizing Nanoparticles to Overcome Anti-PD-1/PD-L1 Immunotherapy Resistance in Non-Small Cell Lung cancer: A Potential Strategy.利用纳米颗粒克服非小细胞肺癌中抗PD-1/PD-L1免疫疗法耐药性：一种潜在策略。
Int J Nanomedicine. 2025 Feb 25;20:2371-2394. doi: 10.2147/IJN.S505539. eCollection 2025.
本文引用的文献
1
Commentary: Induction of Dormancy in Hypoxic Human Papillomavirus-Positive Cancer Cells.评论：缺氧人乳头瘤病毒阳性癌细胞中休眠的诱导
Front Oncol. 2018 Mar 27;8:77. doi: 10.3389/fonc.2018.00077. eCollection 2018.
2
The Role of Indoleamine-2,3-Dioxygenase in Cancer Development, Diagnostics, and Therapy.色氨酸 2,3-双加氧酶在癌症发展、诊断和治疗中的作用。
Front Immunol. 2018 Jan 31;9:151. doi: 10.3389/fimmu.2018.00151. eCollection 2018.
3
Blockade of IDO-kynurenine-AhR metabolic circuitry abrogates IFN-γ-induced immunologic dormancy of tumor-repopulating cells.阻断 IDO-犬尿氨酸-AhR 代谢通路可消除 IFN-γ 诱导的肿瘤再生细胞免疫休眠。
Nat Commun. 2017 May 10;8:15207. doi: 10.1038/ncomms15207.
4
Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives.色氨酸 2,3-双加氧酶在人类癌症中的表达：临床和免疫观点。
Clin Cancer Res. 2011 Nov 15;17(22):6985-91. doi: 10.1158/1078-0432.CCR-11-1331. Epub 2011 Nov 8.
5
IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism.吲哚胺2,3-双加氧酶1（IDO1）和吲哚胺2,3-双加氧酶2（IDO2）在人类肿瘤中表达：左旋而非右旋1-甲基色氨酸抑制色氨酸分解代谢。
Cancer Immunol Immunother. 2009 Jan;58(1):153-7. doi: 10.1007/s00262-008-0513-6. Epub 2008 Apr 17.
Zotero 插件